◢ TECHNICA.BIOBIOTECH ECOSYSTEM INTELLIGENCE
technica.bio / ADC Landscape / Pfizer (Seagen)
ADC Landscape

Pfizer (Seagen)

Tissue Factor · Cervical cancer

ApprovedAntibody–Drug Conjugates
Target
Tissue Factor
Payload
MMAE
Payload class
Auristatin
Linker
Cleavable val-cit
Indication
Cervical cancer
Phase
Approved
Partner
Genmab

Overview

First and only approved Tissue Factor ADC. Genmab antibody + Seagen conjugation — opened a novel target class.

Technology

Pfizer (Seagen) works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.

Read the Antibody–Drug Conjugates brief →

Related companies

Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Roche / Genentech
HER2

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

No spam · ~1–2 emails/month · unsubscribe anytime.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.